MI Sign Up for eTOC Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]
Author:
Keyword(s):
Year:  Vol:  Page: 


Receive this page by email each issue: [Sign up for eTOCs]

Cover Image
Other Issues:
Previous Next
Contents: August 1 2006, Volume 6, Issue 4   [Index by Author]  [Cover Caption]
      Down Viewpoints
      Down Reviews
      Down Speaking of Pharmacology
      Down Reflections
      Down Nascent Transcripts
      Down Beyond the Bench
      Down Net Results
      Down Outliers
Find articles in this issue containing these words:
[Search ALL Issues]


Table of Contents (PDF) | Editorial Board (PDF) | Front Matter (PDF) | Back Matter (PDF) | Advertising (PDF) |
Professional Opportunities (PDF)
To see an article, click its [Full Text] or [PDF] link. To review many summaries, check the boxes to the left of the titles you want, and click the 'Get All Checked Summary(s)' button. To see one summary at a time, click its [Summary] link.

Viewpoints:Back

Dispatches from the Frontlines of Research - edited by John W. Nelson

Paula H. Stern
The Calcineurin-NFAT Pathway and Bone: Intriguing New Findings
Mol. Interv. 2006 6: 193-196. [Summary] [Full Text] [PDF]  

Wolfgang Sadée and Laura Bohn
How Specific Are "Target-Specific" Drugs? Celecoxib as a Case in Point
Mol. Interv. 2006 6: 196-198. [Summary] [Full Text] [PDF]  

R E V I E W S:Back

Ravindra Rajakariar, Muhammad M. Yaqoob, and Derek W. Gilroy
COX-2 in Inflammation and Resolution
Mol. Interv. 2006 6: 199-207. [Summary] [Full Text] [PDF]  

In view of the widespread and effective use of the nonsteroidal anti-inflammatory drugs (NSAIDs), the importance of limiting the side effects of these agents is self-evident. A major goal for both clinicians and drug developers has thus been to improve the specificity with which novel NSAIDs would inhibit their canonical targets, the cyclooxygenase (COX) enzymes. A number of lessons, in a variety of arenas, have been learned in the pursuit of this goal. Some of these lessons have unearthed new challenges in understanding the biology and pharmacology of the COX enzymes. Particularly important is the growing recognition that the inhibition of the COX enzymes, even with the attainment of absolute specificity for one or both of the major COX isoforms, may itself undermine anti-inflammatory therapy or even exacerbate inflammatory disease.

Elizabeth Jonas
BCL-xL Regulates Synaptic Plasticity
Mol. Interv. 2006 6: 208-222. [Summary] [Full Text] [PDF]  

Mitochondria produce energy in the form of ATP for highly energy-dependent processes of synaptic vesicle recycling and the operation of ion pumps. Mitochondrial localization to presynaptic sites alters the kinetics of transmitter release by the localized production of ATP and by calcium buffering. BCL-xL changes the conductance of mitochondrial membranes and alters mitochondrial bioenergetics to enhance the life of the synapse. Therapeutic attempts to modulate neuroplasticity and other synaptic activities may thus rest on a more thorough understanding of the organellar trafficking and constitution of neurons.

Allan E. Rettie and Guoying Tai
The Pharmocogenomics of Warfarin: Closing in on Personalized Medicine
Mol. Interv. 2006 6: 223-227. [Summary] [Full Text] [PDF]  

As with most drugs, the prescription of warfarin is a balancing act. In this case, the patient who receives too much is at risk for hemorrhagic complications, whereas the patient who receives too little may not be adequately protected against thromboembolism. Dose-response curves for warfarin are especially complex, and the basis of this complexity lies in part in the interindividual variability among patient genomes. Research into the pharmacogenomics of warfarin responsiveness, based on an appreciation of the multiple gene products that metabolize or mediate the efficacy of the drug, has arisen as a model for the considerations that must me addressed in bringing personalized medicine into practice.

D E P A R T M E N T S:Back

Speaking of Pharmacology:Back

Benedict R. Lucchesi and Darrell R. Abernethy
Speaking of Pharmacology
Mol. Interv. 2006 6: 185. [Full Text] [PDF]  

Reflections:Back

Science in the cultural context

Stanley Scheindlin
Rare Diseases, Orphan Drugs, and Orphaned Patients
Mol. Interv. 2006 6: 186-191. [Full Text] [PDF]  

Nascent Transcripts:Back

Emerging concepts from the recent literature
Mol. Interv. 2006 6: 192. [Full Text] [PDF]  

Beyond the Bench:Back

Representations of pharmacology and science in the media

Christie Carrico
Breaking the Mold: A Lesson in Perseverance
Mol. Interv. 2006 6: 228-229. [Full Text] [PDF]  

Net Results:Back

Sites of interest on the World Wide Web

Sites of interest on the World Wide Web—edited by David Roman
Mol. Interv. 2006 6: 230. [Full Text] [PDF]  

Outliers:Back

 Cartoon

Outliers
Mol. Interv. 2006 6: 236. [Full Text] [PDF]  

To see an article, click its [Full Text] link. To review many summaries, check the boxes to the left of the titles you want, and click the 'Get All Checked Summary(s)' button. To see one summary at a time, click its [Summary] link.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.